Gland Pharma Q3 FY26 Results: Revenue up 22% YoY to ₹16,954 Crore, Adj. PAT up 37%
Gland Pharma reported Q3 FY26 consolidated revenue of ₹16,954 crore, up 22% YoY. Adjusted PAT rose 37% YoY to ₹2,797 crore. The US market grew 19% and Europe 54% YoY. M/s. Grant Thornton Bharat LLP was reappointed as Internal Auditors for FY26-27.
The announcement includes financial results with significant year-on-year growth, which are material information for investors. The reappointment of internal auditors is also a key corporate action.
The company reported strong year-on-year growth in revenue and adjusted profit after tax, along with healthy EBITDA margins. Positive commentary from the Executive Chairman and CEO further supports the positive sentiment.
Gland Pharma Limited announced its financial results for the third quarter and nine months ended December 31, 2025. The company reported a consolidated revenue from operations of ₹16,954 crore for Q3 FY26, a 22% increase year-on-year, and ₹46,879 crore for the nine months, a 12% increase YoY. Adjusted EBITDA grew by 25% YoY to ₹4,490 crore in Q3 FY26, with an EBITDA margin of 26%. Adjusted PAT increased by 37% YoY to ₹2,797 crore for the quarter and by 33% YoY to ₹6,789 crore for the nine months.
The company's performance was driven by double-digit growth in key markets like the US and Europe, with the US market showing a 19% YoY revenue increase and Europe seeing a significant 54% YoY growth. The company also saw a 32% YoY increase in its India business.
In addition to the financial results, the Board of Directors approved the unaudited financial results for the quarter and nine months ended December 31, 2025. The Board also reappointed M/s. Grant Thornton Bharat LLP as the Internal Auditors for the financial year 2026-27, effective from April 1, 2026.
An exceptional item of ₹243.46 million was recognized during the quarter related to the implications of the New Labour Codes, impacting gratuity and leave liability. The company's R&D investments increased to ₹650 million in Q3 FY26 from ₹437 million in the previous year.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.